We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

By LabMedica International staff writers
Posted on 22 Sep 2025

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. More...

Standard care can be hindered by delays in identifying the type of transfusion needed to stop bleeding. Now, a real-time blood-monitoring approach has shown potential to provide rapid, detailed insights into clotting, bringing hospitals closer to faster and more effective emergency care.

Researchers from the Keck School of Medicine of USC (Los Angeles, CA, USA) conducted a comprehensive review of viscoelastic testing (VET), a minimally invasive diagnostic technology. VET detects how well blood is clotting and identifies which blood components—such as plasma, platelets or whole blood—are most effective for treating hemorrhage. Already approved by the U.S. FDA for use in surgeries and trauma, the test is not yet standard in maternity care.

The review analyzed findings from 156 studies and included interviews with patients, providers and policymakers. Evidence suggests VET can improve management of postpartum hemorrhage, but only two randomized controlled trials were identified, highlighting the need for stronger data. The review, published in the International Journal of Obstetric Anesthesia, underscores that large-scale U.S.-based research is essential to confirm its clinical impact in maternity settings.

Adopting VET could reduce maternal deaths and improve precision in transfusion practices, preventing unnecessary use of costly whole blood products. Its potential extends beyond survival benefits, with implications for reducing health disparities, as Black women and women in rural areas face higher maternal mortality rates. Researchers recommend multicenter randomized trials and standardized protocols to guide adoption, ensuring VET is implemented effectively in obstetric care.

“Because it is a point-of-care test that can be done at a patient’s bedside, it provides fast and detailed results within minutes, helping physicians make treatment decisions in real time,” said Carla Janzen, MD, PhD, first author of the publication.

Related Links:
Keck School of Medicine of USC


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.